Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06879041 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 1
Development phase: 95
Enrollment target: 15
Study locations

NCT06879041: Recruiting Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca.

NCT06879041 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 95 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (52% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06879041, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status: Phase 1
Development phase: 95 participants
Enrollment target: 15
Study locations

Study Summary

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG AZD2287
DRUG AZD2275
DRUG AZD2284

Study Locations (15)

Other

Research Site - East Melbourne
Research Site - CapeTown
Research Site - Durban
Research Site - Pretoria

Florida

Research Site - Miami
Research Site - Tampa

California

Research Site - Palo Alto

Illinois

Research Site - Chicago

Louisiana

Research Site - Metairie

Massachusetts

Research Site - Boston

Minnesota

Research Site - Rochester

Nebraska

Research Site - Omaha

Trial Details

Field	Value
Enrollment Target	95 participants
Start Date	2025-03-10
Est. Completion	2029-04-16
Phase	Phase 1

AstraZeneca

1,285 total trials

What NCT06879041 shows while recruiting

NCT06879041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (52% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which AZD2287 is the first listed.

NCT06879041 lists 15 locations in 11 states (Other, Florida, California).

Frequently Asked Questions

What is clinical trial NCT06879041 about?

NCT06879041 is a clinical study titled "A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer". The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

What is the current status of trial NCT06879041?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2025-03-10. Estimated completion is 2029-04-16.

What conditions does trial NCT06879041 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06879041?

The interventions under investigation include: AZD2287 (DRUG), AZD2275 (DRUG), AZD2284 (DRUG).

Who is sponsoring clinical trial NCT06879041?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06879041 being conducted?

This trial has 15 study locations across California, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06879041's enrollment target sits among peer trials

95 30th of 69 higher than 40 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06879041, the US trial registry maintained by the National Library of Medicine. NCT06879041 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.